We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
- Authors
Herbst, Roy S; Giaccone, Giuseppe; Schiller, Joan H; Natale, Ronald B; Miller, Vincent; Manegold, Christian; Scagliotti, Giorgio; Rosell, Rafael; Oliff, Ira; Reeves, James A; Wolf, Michael K; Krebs, Annetta D; Averbuch, Steven D; Ochs, Judith S; Grous, John; Fandi, Abderrahim; Johnson, David H
- Abstract
Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance antitumor efficacy of cytotoxics, and combination with paclitaxel and carboplatin had acceptable tolerability in a phase I trial. Gefitinib monotherapy demonstrated unparalleled antitumor activity for a biologic agent, with less toxicity than docetaxel, in phase II trials in refractory, advanced non-small-cell lung cancer (NSCLC). This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 5, p785
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2004.07.215